By Dr Aaron Haubner (Senior Manager of North America Medical Affairs and Market Access at Terumo Blood 2025-06-05T09:00:43
Despite the promise of gene therapies, automated red blood cell exchange (aRBCX) remains an underutilised therapy in the management of sickle cell disease (SCD). In this article, Dr Aaron Haubner and Carly Newton of Terumo Blood and Cell Technologies, highlight the urgent need for partnerships and equitable access to this ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-12T09:31:00Z
Contributor Sugish Pillai, Axel Ziemke and Dr Gary Kusdian
2023-09-27T13:56:39
Sponsored by Euretos
2025-05-14T14:30:00
Sponsored by Abzena
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2023-01-04T16:08:55
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2023-04-04T15:03:09
Sponsored by Agilent
Site powered by Webvision Cloud